ACE-Neuro: A Tailored Exercise Oncology Program for Neuro-Oncology Patients – Study Protocol
Abstract Background Patients with primary brain tumours lack access to exercise oncology and wellness resources. The purpose of the Alberta Cancer Exercise – Neuro-Oncology (ACE-Neuro) study is to assess the feasibility of a tailored neuro-oncology exercise program for patients across Alberta, Canada. The primary outcome is to assess the feasibility of ACE-Neuro. The secondary outcome is to examine preliminary effectiveness of ACE-Neuro on patient-reported outcomes and functional fitness.Methods Neuro-oncology patients with a malignant or benign primary brain tumour that are pre, on, or completed treatment, are >18 years, and able to consent in English are eligible to participate in the study. Following referral from the clinical team to cancer rehabilitation and the study team, participants are triaged to determine their appropriateness for ACE-Neuro or other cancer rehabilitation or physiatry resources. In ACE-Neuro, participants complete a tailored 12-week exercise program with pre-post assessments of patient-reported outcomes, functional fitness, and physical activity. ACE-Neuro includes individual and group-based exercise sessions, as well as health coaching.Conclusion We are supporting ACE-Neuro implementation into clinical cancer care, with assessment of needs enabling a tailored exercise prescription..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 08. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Daun, Julia T. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2021.09.08.21263307 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI032556977 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI032556977 | ||
| 003 | DE-627 | ||
| 005 | 20231205150313.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210911s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.09.08.21263307 |2 doi | |
| 035 | |a (DE-627)XBI032556977 | ||
| 035 | |a (biorXiv)10.1101/2021.09.08.21263307 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Daun, Julia T. |e verfasserin |0 (orcid)0000-0003-0343-6654 |4 aut | |
| 245 | 1 | 0 | |a ACE-Neuro: A Tailored Exercise Oncology Program for Neuro-Oncology Patients – Study Protocol |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Patients with primary brain tumours lack access to exercise oncology and wellness resources. The purpose of the Alberta Cancer Exercise – Neuro-Oncology (ACE-Neuro) study is to assess the feasibility of a tailored neuro-oncology exercise program for patients across Alberta, Canada. The primary outcome is to assess the feasibility of ACE-Neuro. The secondary outcome is to examine preliminary effectiveness of ACE-Neuro on patient-reported outcomes and functional fitness.Methods Neuro-oncology patients with a malignant or benign primary brain tumour that are pre, on, or completed treatment, are >18 years, and able to consent in English are eligible to participate in the study. Following referral from the clinical team to cancer rehabilitation and the study team, participants are triaged to determine their appropriateness for ACE-Neuro or other cancer rehabilitation or physiatry resources. In ACE-Neuro, participants complete a tailored 12-week exercise program with pre-post assessments of patient-reported outcomes, functional fitness, and physical activity. ACE-Neuro includes individual and group-based exercise sessions, as well as health coaching.Conclusion We are supporting ACE-Neuro implementation into clinical cancer care, with assessment of needs enabling a tailored exercise prescription. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Capozzi, Lauren C. |4 aut | |
| 700 | 1 | |a Urgoiti, Gloria Roldan |4 aut | |
| 700 | 1 | |a McDonough, Meghan H. |4 aut | |
| 700 | 1 | |a Easaw, Jacob C. |4 aut | |
| 700 | 1 | |a McNeely, Margaret |4 aut | |
| 700 | 1 | |a Francis, George J. |4 aut | |
| 700 | 1 | |a Williamson, Tanya |4 aut | |
| 700 | 1 | |a Danyluk, Jessica |4 aut | |
| 700 | 1 | |a McLaughlin, Emma |4 aut | |
| 700 | 1 | |a Ospina, Paula A. |4 aut | |
| 700 | 1 | |a de Guzman Wilding, Marie |4 aut | |
| 700 | 1 | |a Radke, Lori |4 aut | |
| 700 | 1 | |a Driga, Amy |4 aut | |
| 700 | 1 | |a Lesiuk, Christine |4 aut | |
| 700 | 1 | |a Culos-Reed, S. Nicole |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 08. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:08 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.09.08.21263307 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 08 |c 11 | ||